NEW YORK – The Alzheimer's Drug Discovery Foundation (ADDF) announced on Wednesday that its Diagnostics Accelerator has invested $10 million into Alamar Biosciences. The funding will be used to seek ...
The firm said that the unsecured $1.5 billion revolving credit facility through 2030 replaces another $1.5 billion credit facility through 2026.
Physicians Toxicology Laboratory had been accused of encouraging client healthcare practices to order drug tests for all patients regardless of medical need.
Rounding out the other four largest financing rounds in 2024 are proteomics company Alamar Biosciences' $128 million Series C funding round, Karius' and Cytovale's $100 million raises, and early ...
The funding will be used to expand the firm's global services, enhance its core platforms, and accelerate the development of pathology foundational models.